9 results about "Lamina propria" patented technology

The invention discloses bifidobacterium animalis and application thereof in allergic rhinitis products, and belongs to the technical field of microorganisms. The technical problem to be solved is that the existing common allergic rhinitis treatment means cannot meet the requirements of patients on safety, long-acting effect and treatment cycle. The invention provides an animal bifidobacterium subsp. Lactis Def +, and after an effective dose of animal bifidobacterium subsp. Lactis Def + is applied to a subject, the animal bifidobacterium subsp. Lactis Def + is found to be capable of remarkably relieving the allergic rhinitis symptom. Specifically, the symptoms of sneezing, dry nose and rhinocnesmus are reduced; the number of nasal septum mucosa intrinsic layer inflammation infiltration cells and nasal septum mucosa epithelium pathological changes are reduced; the IgA and IgE levels of serum are reduced; the levels of proinflammatory factors IL-4, IL-5 and IL-13 are reduced; the normal spleen index is maintained; the imbalance state of Th1 / Th2 and Th17 / Treg is effectively improved, and the body immunity is improved; a safe and long-acting scheme is provided for allergic rhinitis diseases.

Apparatuses, systems and methods are provided for treating pulmonary tissues via delivery of energy, generally characterized by high voltage pulses, to target tissue using a pulmonary tissue modification system (e.g., an energy delivery catheter system). Example pulmonary tissues include, without limitation, the epithelium (the goblet cells, ciliated pseudostratified columnar epithelial cells, and basal cells), lamina propria, submucosa, submucosal glands, basement membrane, smooth muscle, cartilage, nerves, pathogens resident near or within the tissue, or a combination of any of these. The system may be used to treat a variety of pulmonary diseases or disorders such as or associated with COPD (e.g., chronic bronchitis, emphysema), asthma, interstitial pulmonary fibrosis, cystic fibrosis, bronchiectasis, primary ciliary dyskinesia (PCD), acute bronchitis and / or other pulmonary diseases or disorders.

This invention discloses an oral ablation detection method and system, belonging to the field of oral detection technology, including: S1, oral tissue sampling; S2, motion compensation; S3, image reconstruction; S4, lesion analysis; S5, ablation planning; S6, ablation execution. This invention utilizes phase-amplitude joint displacement estimation, extracting depth-direction micro-displacement using phase difference and lateral displacement using amplitude centroid shift. This effectively compensates for non-rigid tissue peristalsis caused by swallowing and tongue movements without relying on external markers or high-frequency frame rates, ensuring that the subsequently reconstructed three-dimensional image and ablation target area localization are not distorted due to motion, thus improving the targeting consistency between detection and treatment. Texture analysis at different scales is applied along the oral mucosal epithelium, basement membrane zone, and lamina propria, and depth-adaptive weights are assigned based on the pathological sensitivity differences of each layer, highlighting the probabilistic response of early cancerous areas.

This invention discloses an intestinal organoid eversion model for simulating dairy product absorption and its applications, belonging to the field of biology. The epithelial cells in the intestinal organoid eversion model provided by this invention exhibit the same polarity as those in the human body, thus accurately simulating the dynamic material exchange environment of the "intestinal lumen-epithelium-lamina propria," overcoming the shortcomings of traditional static culture or animal models in terms of structural simulation and physiological relevance. The method provided by this invention can effectively distinguish between receptor-mediated specific transport and non-specific diffusion of lactoferrin, providing high-precision data support for absorption mechanism research. Compared to traditional animal experiments or human trials, this method has a shorter experimental cycle, requires no complex ethical approvals, and standardizes reagents and operating procedures, significantly improving the research and development efficiency of functional components such as dairy products.

Described herein are cholix-IL-10 fusion proteins, and methods of use thereof, which can be characterized by a distinct response in an individual when administered. This distinct response can comprise changes in levels of one or more markers in the individual and / or co-localization of IL-10 in the Lamina propria of the individual. Further described herein, in some embodiments, are oral formulations of the cholix-IL-10 fusion proteins. Described herein are methods for the purification of an IL-10 delivery construct, including methods for refolding and enrichment, which can result in maintenance of a high percentage of the IL-10 delivery constructs in the biologically active dimer form. Described herein are oral formulations configured for site-specific release of a therapeutic protein in the small intestines or colon. In some cases, the therapeutic protein is in the form of a dimer, such as an IL-10 delivery construct capable of crossing the gut epithelium.

This invention belongs to the field of biomedical technology and relates to a fusion protein, gene, expression vector, genetically engineered bacteria, and their applications. The fusion protein is derived from the fusion of bacterial outer membrane vesicle protein and human PD-L1, or from the fusion of bacterial outer membrane vesicle protein, human PD-L1, and human Fc protein. Genetically engineered bacteria constructed using the fusion gene provided by this invention can release PD-L1-rich outer membrane vesicles, which can effectively penetrate the lamina propria of the mucosa and regulate inflammation inside and outside the intestine. This genetically engineered bacterium exhibits good biosafety, effectively regulating intestinal flora and metabolism, and improving intestinal barrier function; moreover, it shows good oral administration compliance, which is beneficial for clinical trials.

The present invention provides simple method for isolating immune cells from the lamina propria of mouse intestinal tissue, belonging to the field of biotechnology. This simple method for isolating immune cells from the lamina propria of mouse intestinal tissue includes selecting 6-week-old mice. After being raised in a specific environment, the mice are anesthetized and intestinal tissue is taken. The intestinal tissue is washed with precooled PBS and cut into small segments. The digestion solution containing a specific concentration of collagenase VIII and DNase I is incubated at 37° C. and a specific pH value with gentle shaking. After digestion, the solution is filtered through a 70 μm cell sieve and centrifuged at 300×g. The immune cell suspension is obtained by resuspending with PBS buffer and then purified with Percoll medium and resuspended with RPMI1640 medium containing serum, etc.

The present invention provides a method of treating a patient suffering from bladder pain syndrome, said method comprising administering a solution containing a clostridial neurotoxin into the bladder of the patient; increasing the volume of solution comprising the clostridial neurotoxin present within the bladder, thereby applying a mechanical force against the inner surface of the urothelial layer; and maintaining said volume of solution comprising the clostridial neurotoxin present within the bladder at a volume that does not give rise to patient micturition and for a duration of at least 30 minutes, thereby allowing the clostridial neurotoxin to diffuse across the urothelial layer and into the lamina propria, where the clostridial neurotoxin binds to primary sensory afferent nerve fibres, suppresses secretion of neurotransmitters therefrom, and alleviates bladder pain.

The invention discloses an inflammation-targeted drug-loaded microgel precursor based on probiotic spores and a preparation method thereof, and relates to the technical field of biological medicines. Polysaccharide is modified on the surface of a probiotic spore through an amido bond to load a first-line drug for treating IBD, and the outermost layer is chelated with metal ions to form an inflammation-targeted drug-loaded microgel precursor. Compared with the traditional hydrogel, the system has the advantages that the protection effect of the system on the medicine is far better than that of the traditional hydrogel, benefited from the natural germination characteristic of the intestinal tract after spores are orally taken, the medicine-carrying microgel precursor forms the medicine-carrying microgel along with the shedding of the spore shell protein, and the medicine-carrying microgel targets the positively charged inflammatory intestinal epithelium part, so that the targeted controlled release of the medicine is realized, and the intestinal inflammation is reduced; meanwhile, the microgel simulates the effect of an intestinal physical barrier, an artificial mucus coating is formed to prevent harmful bacteria from invading to an intrinsic layer, and the microgel and the probiotics are combined to regulate intestinal flora, so that synergistic treatment of IBD is achieved on the whole.